Get the Stockscreener App
4.33
5.46%
-0.25
Recursion Pharmaceuticals Inc stock is traded at $4.33, with a volume of 17.77M.
It is down -5.46% in the last 24 hours and down -6.88% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
See More
Previous Close:
$4.58
Open:
$4.57
24h Volume:
17.77M
Relative Volume:
0.42
Market Cap:
$2.25B
Revenue:
$64.60M
Net Income/Loss:
$-377.75M
P/E Ratio:
-2.7935
EPS:
-1.55
Net Cash Flow:
$-335.64M
1W Performance:
-8.07%
1M Performance:
-6.88%
6M Performance:
-16.25%
1Y Performance:
-37.97%
1-Day Range:
$4.31
$4.6399
1-Week Range:
$4.31
$5.0899
52-Week Range:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.33 | 2.38B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
RXRX Stock Today: Insider Selling, CEO Transition and Trial Catalyst Shape Recursion Pharmaceuticals’ Outlook (December 2025) - ts2.tech
Recursion rises on new data for asset for polyps - MSN
Recursion Pharmaceuticals: Artificial Intelligence, Real Disappointment (RXRX) - Seeking Alpha
Is Early REC-4881 Trial Success Reframing the AI-Drug Discovery Investment Case For Recursion (RXRX)? - simplywall.st
Cautious Optimism for Recursion Pharmaceuticals: Promising TUPELO Study Results Lead to Hold Rating - TipRanks
Norges Bank Buys Shares of 3,169,938 Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Is There an Opportunity in Recursion Pharmaceuticals After Recent AI Drug Discovery Rally? - Yahoo Finance
Recursion Pharmaceuticals Reports Positive TUPELO Trial Results - TipRanks
Recursion Pharmaceuticals reports positive TUPELO trial results - MSN
Recursion Pharmaceuticals (RXRX): Revisiting Valuation After a Tentative Share Price Rebound - simplywall.st
Why Recursion Pharamaceuticals Topped the Market Today - MSN
Why Recursion Pharamaceuticals Topped the Market Today - The Motley Fool
Recursion Pharmaceuticals: Unraveling the Surge - timothysykes.com
Recursion Pharmaceuticals (RXRX) up 6.5% since last earnings report: Can it continue? - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap UpTime to Buy? - MarketBeat
Recursion Pharmaceuticals Stock (RXRX) Opinions on Exscientia Merger and TUPELO Trial Data - Quiver Quantitative
Promising Clinical Study Results and FDA Meeting Propel Buy Rating for Recursion Pharmaceuticals - TipRanks
Why Are Shares Of Recursion Pharmaceuticals Higher Today? - Benzinga
Recursion Pharmaceuticals Jumps as FAP Drug Candidate Shows Durable Efficacy - TradingPedia
Why Recursion Pharmaceuticals Shares Are in Focus Today - TipRanks
Recursion's Tupelo trial phase 1b/2 results show polyp burden reductions in FAP at 25 weeks - marketscreener.com
Recursion Pharmaceuticals stock surges after positive FAP trial data By Investing.com - Investing.com UK
Recursion’s FAP drug shows durable polyp reduction in phase 1b/2 trial - Investing.com
RXRX: REC-4881 achieved rapid, durable polyp burden reduction in FAP with a favorable safety profile - TradingView
Recursion Pharmaceuticals Announces Positive Phase 1b/2 Results for REC-4881 in FAP - TradingView
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO - GlobeNewswire
Recursion Pharmaceuticals (RXRX) Is Up 8.0% After TUPELO REC-4881 Trial Data ReleaseWhat's Changed - Yahoo Finance
Jim Cramer on Recursion: "It Is so Low That It Comes in Under the Category of Speculative" - Finviz
Jim Cramer on Recursion: “It Is so Low That It Comes in Under the Category of Speculative” - Insider Monkey
Growth Value: Can Recursion Pharmaceuticals Inc stock maintain growth trajectoryQuarterly Portfolio Report & AI Enhanced Trading Alerts - moha.gov.vn
Recursion pharma CEO Gibson sells $185,200 in shares - Investing.com
Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 220,000 Shares of Stock - MarketBeat
Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue? - sharewise.com
Jim Cramer: This Health Care Stock Has Been 'Horrendous' - Benzinga
Recursion Pharmaceuticals Registers Resale of 7 Million Shares - MSN
Recursion Pharmaceuticals Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Recursion Pharmaceuticals: Is It the Right Time to Buy? - StocksToTrade
Cramer's Lightning Round: Recursion Pharmaceuticals 'has been horrendous' - CNBC
Recursion Pharmaceuticals Insider Sold Shares Worth $961,400, According to a Recent SEC Filing - marketscreener.com
Recursion Pharmaceuticals: Is This Just The Beginning? - timothysykes.com
A Look At The Fair Value Of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - 富途牛牛
RECURSION PHARMACEUTICALS INC (RXRX.MX) Q1 FY2025 earnings call transcript - Yahoo Finance
Recursion Pharmaceuticals Stock (RXRX) Opinions on Exscientia Merger and Clinical Data Readout - Quiver Quantitative
Miss These Genesis Mission Stocks, and You’ll Regret It for a Decade - InvestorPlace
Costco, AMD, Recursion Pharmaceuticals, Cipher Mining And Snowflake: Why These 5 Stocks Are On Investors' Radars Today - AOL.com
Capital Fund Management S.A. Has $3.65 Million Stock Holdings in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Can Recursion Pharmaceuticals Inc. stock continue upward trendQuarterly Profit Report & Advanced Swing Trade Entry Alerts - Newser
Is Recursion Pharmaceuticals Inc. stock attractive for hedge fundsMarket Trend Review & Verified Technical Signals - Newser
Quadrature Capital Ltd Takes Position in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion to Host Webinar on Tupelo Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis on Dec. 8 - TradingView
Recursion to present updated FAP trial data of REC-4881 in webinar - Investing.com Australia
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Recursion Pharmaceuticals Inc Stock (RXRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Borgeson Blake | Director |
Dec 02 '25 |
Sale |
4.37 |
220,000 |
961,400 |
6,869,863 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):